<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682565</url>
  </required_header>
  <id_info>
    <org_study_id>CY 1221</org_study_id>
    <nct_id>NCT00682565</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics (PK) and Tolerability of Intravenous (IV) and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina</brief_title>
  <official_title>Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytokinetics</source>
  <brief_summary>
    <textblock>
      This study investigates whether symptom-limited exercise capacity in ischemic cardiomyopathy
      patients with angina is deleteriously affected by treatment with CK-1827452.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Exercise Duration During ETT-3 vs. ETT-B</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Stopping ETT-3 for Angina at Any Stage</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With 1 mm ST Segment Depression During ETT-3</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Heart Failure</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Mid Dose CK-1827452 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CK-1827452 or placebo 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose CK-1827452 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CK-1827452 or placebo 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-1827452</intervention_name>
    <description>I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr</description>
    <arm_group_label>Mid Dose CK-1827452 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-1827452</intervention_name>
    <description>12.5mg oral immediate release capsule</description>
    <arm_group_label>Mid Dose CK-1827452 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-1827452</intervention_name>
    <description>I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr</description>
    <arm_group_label>High Dose CK-1827452 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-1827452</intervention_name>
    <description>25mg oral immediate release capsule</description>
    <arm_group_label>High Dose CK-1827452 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>I.V. infusion for 20 hours</description>
    <arm_group_label>Mid Dose CK-1827452 or Placebo</arm_group_label>
    <arm_group_label>High Dose CK-1827452 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo oral immediate release capsule</description>
    <arm_group_label>Mid Dose CK-1827452 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo oral immediate release capsule</description>
    <arm_group_label>High Dose CK-1827452 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient has signed an Informed Consent Form/Patient Information Sheet for this
             study approved by the governing Institutional Review Board (IRB) or Independent Ethics
             Committee (IEC).

          2. The patient is at least 18 years old.

          3. The patient has ischemic heart disease documented by any one or more of the following:

               -  A history of myocardial infarction documented by elevated CPK-MB, troponin I or
                  T, or the presence of electrocardiographic Q waves consistent with myocardial
                  infarction.

               -  Coronary angiography demonstrating at least 1 major epicardial coronary artery
                  (i.e., left main, left anterior descending, left circumflex, or right coronary
                  artery) with a stenosis of at least 60% diameter or greater but excluding
                  stenosis of the left main coronary artery unless revascularized by coronary
                  artery bypass grafting.

          4. The patient has a history of ≥ 1 episode of exercise induced angina within 2 months
             prior to the initial screening visit.

          5. The patient has been taking a beta blocker and an ACE inhibitor (and/or an ARB) for at
             least 4 weeks. If prescribed, diuretics must have been administered for at least 4
             weeks prior to the initial screening visit.

          6. The patient is NYHA Class II-III at the time of enrollment and has been so for ≥ 3
             months prior to the initial screening visit.

          7. The patient has a history of a left ventricular ejection fraction (LVEF) ≤ 35%.

          8. The patient has a history of EITHER a left ventricular end-diastolic diameter ≥ 55 mm,
             OR a left ventricular end-diastolic diameter index ≥ 32 mm/m2.

          9. The patient can be expected to complete at least 4 minutes of a Modified Naughton ETT
             (see Appendix B).

         10. For female patients only: The patient is post-menopausal (≥ 1 year) or sterilized, or
             if she is of childbearing potential, she is not breastfeeding, her pregnancy test is
             negative, she has no intention to become pregnant during the course of the study, and
             she is using contraceptive drugs or devices.

        Exclusion Criteria:

          1. The patient has acute myocarditis; clinically significant restrictive, constrictive,
             or hypertrophic obstructive cardiomyopathy; or clinically significant congenital heart
             disease.

          2. The patient has a SBP &gt; 160 mmHg, documented on at least 3 separate occasions, at
             least 10 minutes apart.

          3. The patient has a DBP &gt; 90 mmHg, documented on at least 3 separate occasions, at least
             10 minutes apart.

          4. The patient has levels of troponin I or T, or CPK-MB &gt; the upper limit of normal at
             any time from 6 weeks prior to the Initial Screening Visit (Visit 1) and up to
             randomization.

          5. The patient has severe aortic or mitral stenosis.

          6. The patient has had an acute coronary syndrome, transient ischemic attack, or
             revascularization procedure within 6 weeks of the Initial Screening Visit (Visit 1).

          7. The patient has significant co-morbid conditions (i.e., lung disease, arthritis,
             peripheral vascular disease) that may limit his or her treadmill exercise capacity.

          8. The patient has renal impairment defined by a calculated creatinine clearance &lt; 30
             cc/min or a need for renal replacement therapy.

          9. The patient has known hepatic impairment defined by a total bilirubin &gt; 3 mg/dL, or an
             ALT or AST &gt; 2 times the upper limit of normal.

         10. The patient has received an investigational drug or device within 30 days or 5
             half-lives, whichever is greater, of randomization.

         11. The patient weighs &gt; 120 kg.

         12. The patient has a body temperature &gt; 38 ° C, confirmed by at least 2 successive
             measurements, at least 10 minutes apart.

         13. The patient has any laboratory abnormality which, in the opinion of the investigator,
             should preclude his or her participation in the study.

         14. The patient has had any prior treatment with CK-1827452.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tbilisi State Medical University Clinic #1</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio-Reanimation Centre</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Therapy</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Clinical Hospital of Tbilisi #2</name>
      <address>
        <city>Tbilisi</city>
        <zip>0164</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Services Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altay Territory Cardiology Dispensary</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #1</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #59</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #64</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Municipal Clinical Hospital #4</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Center of Heart, Blood and Endocrinology n.a. Almazov</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centre for Cardiology n.a. Almazov under Roszdrav</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Cardiology Center</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <results_first_submitted>November 30, 2009</results_first_submitted>
  <results_first_submitted_qc>February 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2010</results_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andrew Wolff, M.D., F.A.C.C., Chief Medical Officer</name_title>
    <organization>Cytokinetics, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mid Dose Active Drug</title>
          <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="P2">
          <title>High Dose Active Drug</title>
          <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="P3">
          <title>All Placebo</title>
          <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mid Dose Active Drug</title>
          <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="B2">
          <title>High Dose Active Drug</title>
          <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="B3">
          <title>All Placebo</title>
          <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="10.0"/>
                    <measurement group_id="B2" value="62.6" spread="8.1"/>
                    <measurement group_id="B3" value="62.3" spread="9.8"/>
                    <measurement group_id="B4" value="63.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)</title>
        <description>The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.</description>
        <time_frame>1 day</time_frame>
        <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O2">
            <title>High Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O3">
            <title>All Placebo</title>
            <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)</title>
          <description>The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.</description>
          <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B</title>
        <description>The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.</description>
        <time_frame>1 day</time_frame>
        <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O2">
            <title>High Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O3">
            <title>All Placebo</title>
            <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B</title>
          <description>The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.</description>
          <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Exercise Duration During ETT-3 vs. ETT-B</title>
        <time_frame>1 day</time_frame>
        <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O2">
            <title>High Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O3">
            <title>All Placebo</title>
            <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Exercise Duration During ETT-3 vs. ETT-B</title>
          <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="113.1"/>
                    <measurement group_id="O2" value="40.5" spread="70.6"/>
                    <measurement group_id="O3" value="60.1" spread="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Stopping ETT-3 for Angina at Any Stage</title>
        <description>This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B.
Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina.</description>
        <time_frame>1 day</time_frame>
        <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O2">
            <title>High Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O3">
            <title>All Placebo</title>
            <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Stopping ETT-3 for Angina at Any Stage</title>
          <description>This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B.
Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina.</description>
          <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With 1 mm ST Segment Depression During ETT-3</title>
        <description>ST Segment Depression measured by Electrocardiography while performing ETT-3.</description>
        <time_frame>1 day</time_frame>
        <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3. However, majority of patients did not have ECGs assessable (per protocol) for 1 mm ST depression.</population>
        <group_list>
          <group group_id="O1">
            <title>Mid Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O2">
            <title>High Dose Active Drug</title>
            <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
          <group group_id="O3">
            <title>All Placebo</title>
            <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With 1 mm ST Segment Depression During ETT-3</title>
          <description>ST Segment Depression measured by Electrocardiography while performing ETT-3.</description>
          <population>The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3. However, majority of patients did not have ECGs assessable (per protocol) for 1 mm ST depression.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 - 3 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 Active Drug</title>
          <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2 Active Drug</title>
          <description>CK-1827452 20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="E3">
          <title>All Placebo</title>
          <description>20 hour infusion followed by 6 days three times a day oral dose and a final single oral dose</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
          <description>All Patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <description>Reported as unrelated to treatment by Investigator but upgraded to possibly related by the sponsor.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post-procedural Myocardial Infarction</sub_title>
                <description>Reported as unrelated to treatment by Investigator.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor intends to publish the results of the trial in collaboration with the Investigators.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Cytokinetics, Inc.</organization>
      <phone>650-624-3053</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

